Pipeline
TriTec 1
TriTec-001 is an optimized version of the highly potent hexavalent single-domain antibody-based TNFR2 agonist 3xNb:C188-Fc(FES) (Anany et al., 2025; Cell Chem Biol. 2025 Oct 16;32(10):1279-1292.e6). Tritec-1 efficiently expands regulatory T-cells (Tregs) and is not inhibited by approved anti-TNF antibodies. TrimmunoTec is now preparing to launch a phase study with TriTec-001 in GvHD prophylaxis.
TriTec 2
TriTec-002 is a conditional bispecific TNFR1 agonist. TriTec-2 binds TNFR1 and an antigen aberrantly expressed in diverse tumors. In the absence of the targeted tumor associated antigen (TAA), TriTec-2 binds TNFR1 without triggering TNFR1 signaling but it acquires a strong TNFR1 stimulatory activity in TAA-bound form. The special mode of action of TriTec-2 limits the dangerous systemic activation of TNFR1 and promises safe conditional activation of TNFR1’s cytotoxic and inflammatory effects in the tumor.
TriTec 3
TriTec-003 is a conditional tetraspecific CD40 agonist. TriTec-3 binds CD40 and three different tumor associated antigens (TAAs). In the absence of the targeted TAAs, TriTec-3 binds CD40 without triggering CD40 signaling but it acquires a strong CD40 stimulatory activity when bound by at least one of its three target antigens. The special mode of action of TriTec-3 limits the risk of a cytokine storm resulting from systemic CD40 activation.
